| Trial ID: | L0831 |
| Source ID: | NCT03060538
|
| Associated Drug: |
BFKB8488A
|
| Title: |
A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver D
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Diabetes Mellitus, Type 2;Non-Alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: BFKB8488A;Other: Placebo
|
| Outcome Measures: |
Percentage of Participants with Adverse Events (AE)Serum BFKB8488A Concentration;Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs)
|
| Sponsor/Collaborators: |
Genentech, Inc.
|
| Gender: |
All
|
| Age: |
18 Years75 Years
|
| Phases: |
Phase 1
|
| Enrollment: |
154
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
| Start Date: |
17/02/2017
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 December 2020
|
| Locations: |
United States;Canada;United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03060538
|
